What are Blas Coll Crespo’s share holdings in Structure Therapeutics after these grants?

After the March 19, 2026 grants, Blas Coll Crespo directly owns 280,878 Ordinary Shares. This total reflects his updated non-derivative holdings following the new RSU grant reported in the Form 4 filing.

Structure Therapeutics (GPCR) CMO receives new stock options and RSU grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Structure Therapeutics Inc. reported that Chief Medical Officer Blas Coll Crespo received equity compensation on March 19, 2026. He was granted an employee stock option for 93,984 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036.

He also received 75,897 Restricted Stock Units, each representing one Ordinary Share, vesting in four equal annual installments starting March 1, 2026, subject to continued service. Following these grants, he directly owns 280,878 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Coll Crespo Blas

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	93,984	$0.00	--
Grant/Award	Ordinary Shares	75,897	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 93,984 shares (Direct); Ordinary Shares — 280,878 shares (Direct)

Footnotes (1)

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

03/23/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coll Crespo Blas

(Last)

(First)

(Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	03/19/2026		A⁽²⁾		75,897	A	$0	280,878	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$16.82⁽³⁾	03/19/2026		A		93,984		⁽⁴⁾	03/18/2036	Ordinary Shares⁽¹⁾	93,984	$0	93,984	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ('ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of March 1, 2026, subject to Reporting Person's continued service on such dates.

3. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.

4. 1/4th of the shares subject to the option shall vest March 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Jun Yoon, Attorney-in-Fact	03/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did GPCR’s CMO Blas Coll Crespo receive on March 19, 2026?

Blas Coll Crespo received stock options for 93,984 Ordinary Shares at a $16.82 exercise price and 75,897 restricted stock units. Both awards are compensation grants that vest over time, subject to his continued service with Structure Therapeutics.

How do the new stock options for GPCR’s CMO vest and when do they expire?

The option vests 25% on March 1, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter. The option expires in 2036, providing a long-term incentive tied to Structure Therapeutics’ share price performance.

How do the restricted stock units granted to GPCR’s CMO vest over time?

The 75,897 RSUs vest one-quarter each year on the anniversaries of March 1, 2026. Vesting is contingent on Blas Coll Crespo’s continued service, aligning his compensation with long-term retention at Structure Therapeutics Inc.

How are Structure Therapeutics’ Ordinary Shares represented by ADSs for GPCR investors?

Each American Depositary Share (ADS) represents three Ordinary Shares of Structure Therapeutics. This means the equity awards reported for Ordinary Shares can be conceptually grouped in threes when considering trading in ADS form on U.S. markets.

Were the equity awards to GPCR’s CMO open-market purchases or compensation grants?

The reported transactions are compensation grants, not market purchases. Both the stock options and restricted stock units are coded as awards, with a zero-dollar transaction price and vesting schedules tied to ongoing service at Structure Therapeutics.